A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized myasthenia gravis, followed by an open-label extension phase.
RecruitingCTIS2023-510026-32-00
Novartis Pharma AGGeneralized Myasthenia Gravis
Start: 2025-06-11Target: 127Updated: 2025-12-10